Breast Cancer Research and Treatment

, Volume 103, Issue 2, pp 185–195 | Cite as

Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff

  • Mogens Groenvold
  • Peter M. Fayers
  • Morten Aagard Petersen
  • Mirjam A. G. Sprangers
  • Neil K. Aaronson
  • Henning T. Mouridsen



Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2) to compare these results against a survey investigating health-care professionals’ knowledge of HRQL.


Patients on adjuvant cyclophosphamide, methotrexate, fluoracil chemotherapy were compared to ‘low-risk’ patients not on chemotherapy (‘control group’). A questionnaire including the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS), and the DBCG 89 Questionnaire was administered six times during a 2-year period. Forty-six experienced health-care professionals were asked which quality-of-life issues they thought were affected by adjuvant chemotherapy.


After 2 years, 159 of 242 patients on chemotherapy and 148 of 199 patients in the control group were alive and recurrence-free and had completed all questionnaires. Worse HRQL during chemotherapy was seen, as had been previously suggested, for 23 of 30 variables. A number of the health-care professionals had not indicated patients to have these side effects. Several side effects persisted after the chemotherapy.


This study provides the most comprehensive description of HRQL in adjuvant therapy to date. The discrepancy between patients and doctors/nurses suggests that patients have been insufficiently informed about the impact of chemotherapy on quality of life. The results of this study provide a basis for information that can be given to patients, and indicate that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.


Breast neoplasms Adjuvant therapy Chemotherapy Outcomes Quality of life 



Supported by the Danish Cancer Society (91-505 and 94 15001).


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  2. 2.
    Chia S, Bryce C, Gelmon K (2005) The 2000 EBCTCG overview: a widening gap. Lancet 365:1665–1666PubMedCrossRefGoogle Scholar
  3. 3.
    van Dam FSAM, Linssen ACG, Engelsman E, van Benthem J, Hanewald GJFP (1980) Life with cytostatic drugs. In: Mouridsen HT, Palshof T (eds) Breast cancer—experimental and clinical aspects. Pergamon, Oxford, pp 229–233Google Scholar
  4. 4.
    Meyerowitz BE, Watkins IK, Sparks FC (1983) Quality of life for breast cancer patients receiving adjuvant chemotherapy. Am J Nurs 83:232–234PubMedCrossRefGoogle Scholar
  5. 5.
    Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4:678–684PubMedGoogle Scholar
  6. 6.
    Levine MN, Guyatt GH, Gent M, Pauw SD, Goodyear MD, Hryniuk WM, Arnold A, Findlay B, Skillings JR, Bramwell VH, Levin L, Bush H, Abu-Zahra H, Kotalik J (1988) Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6:1798–1810PubMedGoogle Scholar
  7. 7.
    Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347:1279–1284PubMedGoogle Scholar
  8. 8.
    Groenvold M (1997) Quality of life in breast cancer adjuvant therapy: validation and pilot testing of a combination of questionnaires. Breast 6:97–107CrossRefGoogle Scholar
  9. 9.
    Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8:723–731PubMedCrossRefGoogle Scholar
  10. 10.
    Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18:233–242PubMedCrossRefGoogle Scholar
  11. 11.
    Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997–2008PubMedCrossRefGoogle Scholar
  12. 12.
    Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, Mackenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658PubMedGoogle Scholar
  13. 13.
    Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, Ganz PA, Fisher B, Wolmark N (2004) Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 86:153–164PubMedCrossRefGoogle Scholar
  14. 14.
    Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ (2005) Patients’ preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 16:1786–1794PubMedCrossRefGoogle Scholar
  15. 15.
    Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A, for the International Breast Cancer Study Group (1998) Quality of life assessment in the adjuvant setting: is it relevant? Recent Results Cancer Res 152:373–389Google Scholar
  16. 16.
    Danish Breast Cancer Cooperative Group (1989) DBCG-89. Program for treatment and follow-up of patients with primary, operable breast cancer [in Danish]. DBCG Secretariat, CopenhagenGoogle Scholar
  17. 17.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishmann SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRefGoogle Scholar
  18. 18.
    Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370PubMedGoogle Scholar
  19. 19.
    Groenvold M, Fayers PM, Petersen MA, Mouridsen HT (2006) Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 98:275–284PubMedCrossRefGoogle Scholar
  20. 20.
    Ringdal GI, Ringdal K (1993) Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 2:129–140PubMedCrossRefGoogle Scholar
  21. 21.
    Osoba D, Zee B, Pater J, Warr L, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353–364PubMedCrossRefGoogle Scholar
  22. 22.
    McLachlan SA, Devins GM, Goodwin PJ (1998) Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer 34:510–517PubMedCrossRefGoogle Scholar
  23. 23.
    Groenvold M, Klee MC, Sprangers MAG, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient–observer agreement. J Clin Epidemiol 50:441–450PubMedCrossRefGoogle Scholar
  24. 24.
    Groenvold M, Bjorner JB, Klee MC, Kreiner S (1995) Test for item bias in a quality of life questionnaire. J Clin Epidemiol 48:805–816PubMedCrossRefGoogle Scholar
  25. 25.
    Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organization for Research and Treatment of Cancer, BrusselsGoogle Scholar
  26. 26.
    Groenvold M, Fayers PM (1998) Testing for differences in multiple quality of life dimensions: generating hypotheses from the experience of hospital staff. Qual Life Res 7:479–486PubMedCrossRefGoogle Scholar
  27. 27.
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650PubMedCrossRefGoogle Scholar
  28. 28.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMedGoogle Scholar
  29. 29.
    Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493PubMedCrossRefGoogle Scholar
  30. 30.
    Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146–152PubMedGoogle Scholar
  31. 31.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628–4635PubMedCrossRefGoogle Scholar
  32. 32.
    Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A, Hurny C (2004) Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer 91:1893–1901PubMedCrossRefGoogle Scholar
  33. 33.
    Macquart-Moulin G, Viens P, Bouscary ML, Genre D, Resbeut M, Gravis G, Camerlo J, Maraninchi D, Moatti JP (1997) Discordance between physicians’ estimations and breast cancer patients’ self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer 76:1640–1645PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Mogens Groenvold
    • 1
    • 2
  • Peter M. Fayers
    • 3
    • 4
  • Morten Aagard Petersen
    • 1
  • Mirjam A. G. Sprangers
    • 5
  • Neil K. Aaronson
    • 6
  • Henning T. Mouridsen
    • 7
  1. 1.The Research Unit, Department of Palliative MedicineBispebjerg HospitalCopenhagenDenmark
  2. 2.Department of Health Services ResearchInstitute of Public Health, University of CopenhagenCopenhagenDenmark
  3. 3.Department of Public HealthUniversity of Aberdeen Medical SchoolAberdeenUK
  4. 4.Unit for Applied Clinical ResearchNorwegian University of Science and TechnologyTrondheimNorway
  5. 5.Department of Medical PsychologyAcademic Medical Center, University of AmsterdamAmsterdamThe Netherlands
  6. 6.Division of Psychosocial Research and EpidemiologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  7. 7.Department of Oncology ONK, The Finsen Centre, RigshospitaletUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations